Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 425
Filtrar
1.
Nutrients ; 14(2)2022 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-35057577

RESUMEN

The intermediate state between normal glucose tolerance and overt type 2 diabetes mellitus is associated with micro- and macrovascular diseases, requiring safe and cost-effective treatment measures interventions. A novel source of LC n-3 FAs is Calanus finmarchicus Oil, which showed promising effects on glucose homeostasis in preclinical studies due to anti-obesity effects and/or anti-inflammatory properties. In total, 43 obese patients (BMI: 31.7 ± 5.2 kg/m2) were allocated in the following two groups: (1) Calanus oil group (2 g CO/day) and (2) placebo group (2 g paraffin oil/day). Markers of glucose metabolism, body composition and energy intake were measured at the beginning (t0), after 12 weeks (t12) and 16 weeks (t16). Overall, parameters reflecting abnormal glucose homeostasis and insulin resistance in the liver, including fasting insulin (-2.9 mU/L ± 4.10, p < 0.05), HOMA-IR (-0.9 ± 1.28, p < 0.05) and hepatic insulin resistance index (-1.06 ± 1.72 × 106, p < 0.05) significantly enhanced after a 12-week CO-intervention, while no differences were observed in HbA1c, AUC0-2h Glucose, AUC0-2h Insulin, 2 h plasma glucose and muscle insulin sensitivity index. Our results indicate that Calanus oil causes beneficial effects on glucose metabolism and insulin resistance in obese patients, with clinical relevance to be verified in further studies. In addition, the possible active compounds and their mechanisms of action should be elucidated.


Asunto(s)
Glucemia/metabolismo , Copépodos/química , Grasas Insaturadas en la Dieta/uso terapéutico , Resistencia a la Insulina , Obesidad/tratamiento farmacológico , Estado Prediabético/tratamiento farmacológico , Anciano , Animales , Índice de Masa Corporal , Método Doble Ciego , Ácidos Grasos Omega-3/sangre , Femenino , Homeostasis , Humanos , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Persona de Mediana Edad , Obesidad/metabolismo , Placebos , Estado Prediabético/metabolismo
2.
Sci Rep ; 11(1): 9749, 2021 05 12.
Artículo en Inglés | MEDLINE | ID: mdl-33980877

RESUMEN

Conjugated linoleic acid (CLA) is an isomer of linoleic acid (LA). The predominant dietary CLA is cis-9, trans-11-CLA (c-9, t-11-CLA), which constitutes up to ~ 90% of total CLA and is thought to be responsible for the positive health benefits associated with CLA. However, the effects of c-9, t-11-CLA on Alzheimer's disease (AD) remain to be elucidated. In this study, we investigated the effect of dietary intake of c-9, t-11-CLA on the pathogenesis of an AD mouse model. We found that c-9, t-11-CLA diet-fed AD model mice significantly exhibited (1) a decrease in amyloid-ß protein (Aß) levels in the hippocampus, (2) an increase in the number of microglia, and (3) an increase in the number of astrocytes expressing the anti-inflammatory cytokines, interleukin-10 and 19 (IL-10, IL-19), with no change in the total number of astrocytes. In addition, liquid chromatography-tandem mass spectrometry (LC-MS/MS) and gas chromatographic analysis revealed that the levels of lysophosphatidylcholine (LPC) containing c-9, t-11-CLA (CLA-LPC) and free c-9, t-11-CLA were significantly increased in the brain of c-9, t-11-CLA diet-fed mice. Thus, dietary c-9, t-11-CLA entered the brain and appeared to exhibit beneficial effects on AD, including a decrease in Aß levels and suppression of inflammation.


Asunto(s)
Enfermedad de Alzheimer/dietoterapia , Péptidos beta-Amiloides/metabolismo , Citocinas/metabolismo , Grasas Insaturadas en la Dieta/uso terapéutico , Ácidos Linoleicos Conjugados/uso terapéutico , Enfermedad de Alzheimer/metabolismo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/análisis , Animales , Citocinas/análisis , Modelos Animales de Enfermedad , Humanos , Ratones , Ratones Endogámicos C57BL
3.
Int J Mol Sci ; 21(17)2020 Aug 22.
Artículo en Inglés | MEDLINE | ID: mdl-32842664

RESUMEN

Idiopathic pulmonary fibrosis (IPF) is a chronic disease mainly associated with aging and, to date, its causes are still largely unknown. It has been shown that dietary habits can accelerate or delay the occurrence of aging-related diseases; however, their potential role in IPF development has been underestimated so far. The present review summarizes the evidence regarding the relationship between diet and IPF in humans, and in animal models of pulmonary fibrosis, in which we discuss the bioactivity of specific dietary food ingredients, including fatty acids, peptides, amino acids, carbohydrates, vitamins, minerals and phytochemicals. Interestingly, many animal studies reveal preventive and therapeutic effects of particular compounds. Furthermore, it has been recently suggested that the lung and gut microbiota could be involved in IPF, a relationship which may be linked to changes in immunological and inflammatory factors. Thus, all the evidence so far puts forward the idea that the gut-lung axis could be modulated by dietary factors, which in turn have an influence on IPF development. Overall, the data reviewed here support the notion of identifying food ingredients with potential benefits in IPF, with the ultimate aim of designing nutritional approaches as an adjuvant therapeutic strategy.


Asunto(s)
Ingredientes Alimentarios , Fibrosis Pulmonar Idiopática/microbiología , Microbiota/fisiología , Envejecimiento , Aminoácidos/metabolismo , Animales , Avitaminosis/complicaciones , Grasas Insaturadas en la Dieta/farmacología , Grasas Insaturadas en la Dieta/uso terapéutico , Ingredientes Alimentarios/efectos adversos , Microbioma Gastrointestinal , Humanos , Fibrosis Pulmonar Idiopática/dietoterapia , Pulmón/microbiología , Micronutrientes/metabolismo , Micronutrientes/farmacología , Fitoquímicos/farmacología , Vitaminas/farmacología
4.
Nat Commun ; 10(1): 4007, 2019 09 05.
Artículo en Inglés | MEDLINE | ID: mdl-31488836

RESUMEN

Gut microbiota mediates the effects of diet, thereby modifying host metabolism and the incidence of metabolic disorders. Increased consumption of omega-6 polyunsaturated fatty acid (PUFA) that is abundant in Western diet contributes to obesity and related diseases. Although gut-microbiota-related metabolic pathways of dietary PUFAs were recently elucidated, the effects on host physiological function remain unclear. Here, we demonstrate that gut microbiota confers host resistance to high-fat diet (HFD)-induced obesity by modulating dietary PUFAs metabolism. Supplementation of 10-hydroxy-cis-12-octadecenoic acid (HYA), an initial linoleic acid-related gut-microbial metabolite, attenuates HFD-induced obesity in mice without eliciting arachidonic acid-mediated adipose inflammation and by improving metabolic condition via free fatty acid receptors. Moreover, Lactobacillus-colonized mice show similar effects with elevated HYA levels. Our findings illustrate the interplay between gut microbiota and host energy metabolism via the metabolites of dietary omega-6-FAs thereby shedding light on the prevention and treatment of metabolic disorders by targeting gut microbial metabolites.


Asunto(s)
Dieta Alta en Grasa/efectos adversos , Grasas Insaturadas en la Dieta/uso terapéutico , Ácidos Grasos Insaturados/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Obesidad/metabolismo , Tejido Adiposo/patología , Animales , Línea Celular , Dieta Occidental , Suplementos Dietéticos , Metabolismo Energético , Ácidos Grasos Omega-6/metabolismo , Ácidos Grasos Omega-6/uso terapéutico , Ácidos Grasos Insaturados/metabolismo , Microbioma Gastrointestinal/fisiología , Humanos , Inflamación/metabolismo , Lactobacillus/metabolismo , Ácido Linoleico/metabolismo , Enfermedades Metabólicas/dietoterapia , Enfermedades Metabólicas/metabolismo , Enfermedades Metabólicas/prevención & control , Ratones , Ratones Endogámicos C57BL , Modelos Animales , Ácidos Oléicos/metabolismo
5.
BMJ ; 366: l4697, 2019 08 21.
Artículo en Inglés | MEDLINE | ID: mdl-31434641

RESUMEN

OBJECTIVE: To assess effects of increasing omega-3, omega-6, and total polyunsaturated fatty acids (PUFA) on diabetes diagnosis and glucose metabolism. DESIGN: Systematic review and meta-analyses. DATA SOURCES: Medline, Embase, Cochrane CENTRAL, WHO International Clinical Trials Registry Platform, Clinicaltrials.gov, and trials in relevant systematic reviews. ELIGIBILITY CRITERIA: Randomised controlled trials of at least 24 weeks' duration assessing effects of increasing α-linolenic acid, long chain omega-3, omega-6, or total PUFA, which collected data on diabetes diagnoses, fasting glucose or insulin, glycated haemoglobin (HbA1c), and/or homoeostatic model assessment for insulin resistance (HOMA-IR). DATA SYNTHESIS: Statistical analysis included random effects meta-analyses using relative risk and mean difference, and sensitivity analyses. Funnel plots were examined and subgrouping assessed effects of intervention type, replacement, baseline risk of diabetes and use of antidiabetes drugs, trial duration, and dose. Risk of bias was assessed with the Cochrane tool and quality of evidence with GRADE. RESULTS: 83 randomised controlled trials (mainly assessing effects of supplementary long chain omega-3) were included; 10 were at low summary risk of bias. Long chain omega-3 had little or no effect on likelihood of diagnosis of diabetes (relative risk 1.00, 95% confidence interval 0.85 to 1.17; 58 643 participants, 3.7% developed diabetes) or measures of glucose metabolism (HbA1c mean difference -0.02%, 95% confidence interval -0.07% to 0.04%; plasma glucose 0.04, 0.02 to 0.07, mmol/L; fasting insulin 1.02, -4.34 to 6.37, pmol/L; HOMA-IR 0.06, -0.21 to 0.33). A suggestion of negative outcomes was observed when dose of supplemental long chain omega-3 was above 4.4 g/d. Effects of α-linolenic acid, omega-6, and total PUFA on diagnosis of diabetes were unclear (as the evidence was of very low quality), but little or no effect on measures of glucose metabolism was seen, except that increasing α-linolenic acid may increase fasting insulin (by about 7%). No evidence was found that the omega-3/omega-6 ratio is important for diabetes or glucose metabolism. CONCLUSIONS: This is the most extensive systematic review of trials to date to assess effects of polyunsaturated fats on newly diagnosed diabetes and glucose metabolism, including previously unpublished data following contact with authors. Evidence suggests that increasing omega-3, omega-6, or total PUFA has little or no effect on prevention and treatment of type 2 diabetes mellitus. SYSTEMATIC REVIEW REGISTRATION: PROSPERO CRD42017064110.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/prevención & control , Grasas Insaturadas en la Dieta/uso terapéutico , Prevención Primaria/métodos , Prevención Secundaria/métodos , Adulto , Glucemia/análisis , Diabetes Mellitus Tipo 2/sangre , Suplementos Dietéticos , Ayuno/sangre , Ácidos Grasos Omega-3/uso terapéutico , Ácidos Grasos Omega-6/uso terapéutico , Ácidos Grasos Insaturados/uso terapéutico , Femenino , Hemoglobina Glucada/análisis , Humanos , Insulina/sangre , Resistencia a la Insulina , Masculino , Ensayos Clínicos Controlados Aleatorios como Asunto
6.
Clin Nutr ; 38(3): 1253-1261, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-31060718

RESUMEN

BACKGROUND & AIMS: The purpose of this study was to assess nutritional status, quality of life (QoL) and function in malnourished or at risk for malnutrition community-dwelling (CD) and nursing home-dwelling (NHD) elderly patients with type 2 diabetes mellitus (DM2), receiving treatment with a diabetes-specific oral nutritional supplement (DSONS). METHODS: A prospective, multicentre, observational study was conducted. A DSONS (high-calorie, high-protein, with slow-digestible carbohydrate and high monounsaturated fatty acid - MUFA-content - Glucerna® 1.5 Cal) had been prescribed the week before inclusion. The following assessments were undertaken at baseline (BL), at week 6 (V1) and at month 3 (FV): body mass index (BMI), glycosylated haemoglobin (HbA1c), nutritional status (Mini Nutritional Assessment - MNA), QoL (EQ-5D questionnaire), and functional status (Katz Index - KI of Independence in Activities of Daily Living). The data were reported in the overall population (OP) and in the CD and NHD groups. RESULTS: A total of 402 patients aged 80.8 ± 8.5 years were evaluable (44.5% men), including 61.7% CD and 38.3% NHD. BMI (kg/m2) increased in the OP from 22.0 ± 3.5 at BL to 22.5 ± 3.6 at V1 (p < 0.001) and 23.0 ± 3.7 at the FV (p < 0.001). BMI also increased in the CD group (p < 0.001) and in the NHD group (p < 0.001). HbA1c decreased in the OP from 7.3 ± 1.1% at BL to 7.2 ± 1.0% at V1 and 7.0 ± 0.9% at the FV (p < 0.001), in both the CD (p < 0.001) and the NHD groups (p = 0.020). The mean overall MNA score increased in the OP from 13.1 ± 4.8 at BL to 17.0 ± 4.7 at V1 and 18.6 ± 5.1 at the FV (p < 0.001). The mean overall MNA score also increased in the CD (p < 0.001) and the NHD groups (p < 0.001). The mean overall EQ-5D score improved in the OP from 46.0 ± 18.0 at BL to 54.8 ± 17.5 at V1 and 59.7 ± 18.8 at the FV (p < 0.001). The mean overall EQ-5D score also improved in the CD (p < 0.001) and the NHD groups (p < 0.001). Gastrointestinal adverse events were seen in only 2% of patients. Treatment compliance was 94.4%. CONCLUSIONS: In this study, conducted in routine, multicentre, clinical settings, the treatment with the high-calorie, high-protein, with slow-digestible carbohydrate, and high MUFA content DSNOS - Glucerna® 1.5 Cal-, was associated with improvements in HbA1c, nutritional status, BMI and QoL following 6 weeks and 3 months of treatment in both institutionalised and non-institutionalised elderly patients with diabetes who were malnourished or at risk for malnutrition. A slight improvement in functional status was also observed at 12 weeks. As this is an observational effectiveness study, a randomized controlled trial would be necessary to establish a causal relationship between the DSNOS and the described events.


Asunto(s)
Diabetes Mellitus Tipo 2 , Carbohidratos de la Dieta , Grasas Insaturadas en la Dieta , Estado Nutricional/fisiología , Calidad de Vida , Anciano , Anciano de 80 o más Años , Diabetes Mellitus Tipo 2/dietoterapia , Diabetes Mellitus Tipo 2/epidemiología , Carbohidratos de la Dieta/administración & dosificación , Carbohidratos de la Dieta/uso terapéutico , Grasas Insaturadas en la Dieta/administración & dosificación , Grasas Insaturadas en la Dieta/uso terapéutico , Suplementos Dietéticos , Femenino , Humanos , Masculino , Desnutrición , Cooperación del Paciente/estadística & datos numéricos , Estudios Prospectivos , Resultado del Tratamiento
7.
Nutrients ; 10(12)2018 Dec 06.
Artículo en Inglés | MEDLINE | ID: mdl-30563193

RESUMEN

Fish intake and docosahexaenoic acid (DHA), a nutrient found in fish, have been favorably linked to several pregnancy outcomes. The risk of early preterm birth (ePT, <34 weeks gestation) is associated with low fish intake and DHA blood levels and can be reduced by supplemental DHA. Here, we summarize the evidence linking blood DHA levels with risk for ePT birth, and based on the available studies, propose that women who are pregnant or trying to become pregnant aim for a red blood cell (RBC) DHA value of at least 5% (of total RBC fatty acids). In the US, ~70% of women of childbearing age are likely below this cut-point, and dietary intake data suggest that this group, including pregnant women, consumes ~60 mg/day DHA and that >90% of this group do not take an omega-3 supplement. Since the recommendations for women to consume fish and to take a 200 mg DHA supplement during pregnancy are not being heeded generally, there is a need to motivate practitioners and pregnant women to attend to these recommendations. Having an objective prenatal blood DHA test could provide such motivation. More research is needed to test the clinical utility of this proposed target prenatal DHA level.


Asunto(s)
Dieta , Grasas Insaturadas en la Dieta/sangre , Suplementos Dietéticos , Ácidos Docosahexaenoicos/sangre , Resultado del Embarazo , Nacimiento Prematuro , Atención Prenatal , Adulto , Animales , Análisis Químico de la Sangre , Grasas Insaturadas en la Dieta/administración & dosificación , Grasas Insaturadas en la Dieta/uso terapéutico , Ácidos Docosahexaenoicos/administración & dosificación , Ácidos Docosahexaenoicos/uso terapéutico , Eritrocitos/metabolismo , Ácidos Grasos Omega-3/sangre , Femenino , Peces , Edad Gestacional , Humanos , Recién Nacido , Motivación , Selección de Paciente , Embarazo , Mujeres Embarazadas , Nacimiento Prematuro/etiología , Nacimiento Prematuro/prevención & control , Valores de Referencia , Factores de Riesgo
8.
Nutr Res ; 58: 84-94, 2018 10.
Artículo en Inglés | MEDLINE | ID: mdl-30340818

RESUMEN

Methamphetamine (METH) exposure can cause severe effects to the nervous system; however, the underlying molecular mechanism of neurotoxicity caused by METH is still unclear. Oxidative stress and apoptosis are linked in the pathophysiology of many neurodegenerative diseases. Krill oil (KO) benefits human health via its strong antioxidant ability. Therefore, we hypothesized that KO supplementation might effectively prevent METH-induced neurotoxicity via the inhibition of apoptotic responses and oxidative damages. In this study, PC12 cells were exposed to both METH (3 mmol/L) and KO (0.1, 0.2, 0.4, 0.8 µg/mL) in vitro for 24 h, and the following parameters were measured to detect apoptosis and oxidative stress responses that were triggered by METH: cell viability, the oxidative enzyme system, NO production, ROS production, apoptosis, mitochondrial membrane potential and protein expression of cleaved caspase-3. The results indicate that KO mitigates the apoptotic response post-METH exposure in PC 12 cells by increasing cell viability, decreasing protein expression of cleaved caspase-3, reducing apoptotic rates, and decreasing dissipation of mitochondrial membrane potential. In addition, the study revealed increases in SOD and GSH activity, and decreases in MDA content, NO and ROS production, suggesting that KO is beneficial in reducing oxidative stress, which may also play a role in the regulation of METH-triggered apoptotic response. Consequently, these data indicate that KO could potentially alleviate METH-induced neurotoxicity via the reduction of apoptotic responses and oxidative damages.


Asunto(s)
Antioxidantes/uso terapéutico , Apoptosis/efectos de los fármacos , Grasas Insaturadas en la Dieta/uso terapéutico , Euphausiacea/química , Metanfetamina/toxicidad , Síndromes de Neurotoxicidad/prevención & control , Estrés Oxidativo/efectos de los fármacos , Animales , Antioxidantes/farmacología , Caspasa 3/metabolismo , Supervivencia Celular , Grasas Insaturadas en la Dieta/farmacología , Suplementos Dietéticos , Glutatión/metabolismo , Malondialdehído/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Neuronas/efectos de los fármacos , Síndromes de Neurotoxicidad/metabolismo , Síndromes de Neurotoxicidad/fisiopatología , Óxido Nítrico/metabolismo , Células PC12 , Ratas , Especies Reactivas de Oxígeno/metabolismo , Superóxido Dismutasa/metabolismo
9.
Food Funct ; 9(9): 4876-4887, 2018 Sep 19.
Artículo en Inglés | MEDLINE | ID: mdl-30160281

RESUMEN

Freshwater clam (Corbicula fluminea) is a traditional liver-protective food in Asia. Recent studies have renewed attention on high cholesterol accumulation and dysregulated cholesterol synthesis in the liver as a critical factor in the progression of nonalcoholic fatty liver disease (NAFLD) to nonalcoholic steatohepatitis (NASH). In this study, we investigated the protective effects of freshwater clam extract (FCE) and its fat fraction (FCE oil) on high-fat, high-cholesterol and cholic acid (HFHC) diet-induced lean steatohepatitis in mice. Mice were fed a HFHC diet containing FCE or FCE oil for 6 weeks. FCE, but not FCE oil, feeding reduced liver injury as indicated by decreased plasma alanine aminotransferase activity. Liver total cholesterol accumulation was reduced after FCE and FCE oil treatment. Accumulation of squalene and desmosterol, the precursors of cholesterol, in the liver was reduced by FCE but not by FCE oil. The caspase-1 (p10) and interleukin (IL)-1ß (p17) protein expressions in the liver were suppressed by both FCE and FCE oil. Therefore, FCE may act as functional food that can reduce steatohepatitis and liver injury by reducing cholesterol accumulation, improving dysregulated cholesterol synthesis and attenuating inflammation.


Asunto(s)
Productos Biológicos/uso terapéutico , Corbicula/química , Suplementos Dietéticos , Lipotrópicos/uso terapéutico , Hígado/metabolismo , Enfermedad del Hígado Graso no Alcohólico/prevención & control , Mariscos/análisis , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/uso terapéutico , Antioxidantes/administración & dosificación , Antioxidantes/química , Antioxidantes/uso terapéutico , Productos Biológicos/administración & dosificación , Productos Biológicos/química , Biomarcadores/sangre , Biomarcadores/metabolismo , Colesterol en la Dieta/efectos adversos , Ácido Cólico/efectos adversos , Dieta Alta en Grasa/efectos adversos , Grasas Insaturadas en la Dieta/uso terapéutico , Femenino , Metabolismo de los Lípidos , Lipotrópicos/administración & dosificación , Lipotrópicos/química , Hígado/inmunología , Hígado/patología , Hígado/fisiopatología , Ratones Endogámicos C57BL , Músculos/química , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Enfermedad del Hígado Graso no Alcohólico/patología , Enfermedad del Hígado Graso no Alcohólico/fisiopatología , Estrés Oxidativo , Distribución Aleatoria , Extractos de Tejidos/administración & dosificación , Extractos de Tejidos/química , Extractos de Tejidos/uso terapéutico
10.
Regul Toxicol Pharmacol ; 94: 234-239, 2018 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-29454011

RESUMEN

Currently accepted that oxidative stress is a triggering event in the melanocytic destruction and is probably involved in the etiopathogenesis of vitiligo disease. Despite numerous investigations, contradictory results were reported about the levels of oxidative stress biomarkers measured in the skin and blood of vitiligo patients. By Electron Paramagnetic Resonance spectroscopy (EPR) and spectrophotometry, we have investigated and compared some oxidative stress biomarkers in the blood of vitiligo patients' before and after UVB Narrow Band 311 nm phototherapy combined with the antioxidant nutritional supplement containing - Vitamin C, Vitamin B1, L -Cysteine, Lipoic Acid, and polyunsaturated fatty acids. Before therapy was found significantly higher levels of CAT activity and MDA compared to the patients after therapy and control group (p < 0.05). Moreover, levels of Asc* radicals in patients before therapy were significantly lower than those measured in controls and patients undergoing therapy (p < 0.05). Our finding, the combined therapy applied to vitiligo patients provoked an increase in the Asc* levels and a decrease in MDA products and also initial repigmentation in the vitiligo spots, made us believe that a combined antioxidant therapy, enriched with vitamin C could lead to improvement of the oxidant-antioxidant balance in vitiligo patients treated with UVB 311 phototherapy.


Asunto(s)
Antioxidantes/uso terapéutico , Fototerapia , Vitíligo/sangre , Vitíligo/terapia , Ácido Ascórbico/sangre , Biomarcadores/sangre , Catalasa/sangre , Cisteína/uso terapéutico , Grasas Insaturadas en la Dieta/uso terapéutico , Femenino , Humanos , Masculino , Malondialdehído/sangre , Estrés Oxidativo , Especies Reactivas de Oxígeno/sangre , Tiamina/uso terapéutico , Ácido Tióctico/uso terapéutico , Vitamina E/uso terapéutico , Vitaminas/uso terapéutico
12.
Artículo en Inglés | MEDLINE | ID: mdl-29141573

RESUMEN

BACKGROUND AND OBJECTIVE: The liver is an organ susceptible to a multitude of injuries that causes liver damage, like steatosis, non-alcoholic steatohepatitis, cirrhosis, hepatocellular carcinoma, and ischemia-reperfusion injury. Extra virgin olive oil (EVOO), presents several protective effects on the liver, reducing hepatic steatosis, hepatocyte ballooning, fibrogenesis, preventing lipid peroxidation, among other effects. Due to its high levels of monounsaturated fatty acids, mainly oleic acid and phenolic compounds, such as hydroxytyrosol and oleuropein, EVOO is able to participate in the activation of different signaling pathways in the hepatocytes involved in the prevention of inflammation, oxidative stress, endoplasmic reticulum stress, mitochondrial dysfunction, and insulin resistance, allowing the prevention or resolution of liver damage. The aim of this work is to offer an update of the molecular effects of EVOO in the liver and its protective properties to prevent the establishment of liver damage through the regulation of different cell-signaling pathways. METHODS: Searches that considered the effects of EVOO in in vivo and in vitro models, whith emphasis in the molecular mechanism of liver tissue damage and prevention and/or treatment of steatosis, steatohepatitis, cirrhosis, hepatocellular carcinoma, and ischemia-reperfusion injury. CONCLUSION: The most relevant molecular effects of EVOO involved in the prevention or resolution of liver damage are: (i) Activation of the nuclear transcription factor erythroid-derived 2-like 2 (Nfr2), inducing the cellular antioxidant response; (ii) Inactivation of the nuclear transcription factor-κB (NF- κB), preventing the cellular inflammatory response; and (iii) Inhibition of the PERK pathway, preventing endoplasmic reticulum stress, autophagy, and lipogenic response.


Asunto(s)
Grasas Insaturadas en la Dieta/uso terapéutico , Calidad de los Alimentos , Alimentos Funcionales , Hígado/metabolismo , Enfermedad del Hígado Graso no Alcohólico/prevención & control , Aceite de Oliva/uso terapéutico , Animales , Antiinflamatorios no Esteroideos/análisis , Antiinflamatorios no Esteroideos/uso terapéutico , Antioxidantes/análisis , Antioxidantes/uso terapéutico , Autofagia , Grasas Insaturadas en la Dieta/análisis , Grasas Insaturadas en la Dieta/normas , Suplementos Dietéticos , Estrés del Retículo Endoplásmico , Alimentos Funcionales/análisis , Humanos , Lipogénesis , Hígado/enzimología , Hígado/inmunología , Enfermedad del Hígado Graso no Alcohólico/dietoterapia , Enfermedad del Hígado Graso no Alcohólico/inmunología , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Aceite de Oliva/química , Aceite de Oliva/normas , Alcohol Feniletílico/análogos & derivados , Alcohol Feniletílico/análisis , Alcohol Feniletílico/uso terapéutico , Transducción de Señal
13.
J Nutr Biochem ; 51: 99-104, 2018 01.
Artículo en Inglés | MEDLINE | ID: mdl-29125992

RESUMEN

At present, high-density lipoprotein (HDL) function is thought to be more relevant than HDL cholesterol quantity. Consumption of olive oil phenolic compounds (PCs) has beneficial effects on HDL-related markers. Enriched food with complementary antioxidants could be a suitable option to obtain additional protective effects. Our aim was to ascertain whether virgin olive oils (VOOs) enriched with (a) their own PC (FVOO) and (b) their own PC plus complementary ones from thyme (FVOOT) could improve HDL status and function. Thirty-three hypercholesterolemic individuals ingested (25 ml/day, 3 weeks) (a) VOO (80 ppm), (b) FVOO (500 ppm) and (c) FVOOT (500 ppm) in a randomized, double-blind, controlled, crossover trial. A rise in HDL antioxidant compounds was observed after both functional olive oil interventions. Nevertheless, α-tocopherol, the main HDL antioxidant, was only augmented after FVOOT versus its baseline. In conclusion, long-term consumption of phenol-enriched olive oils induced a better HDL antioxidant content, the complementary phenol-enriched olive oil being the one which increased the main HDL antioxidant, α-tocopherol. Complementary phenol-enriched olive oil could be a useful dietary tool for improving HDL richness in antioxidants.


Asunto(s)
Antioxidantes/uso terapéutico , Grasas Insaturadas en la Dieta/uso terapéutico , Hipercolesterolemia/dietoterapia , Lipoproteínas HDL/sangre , Aceite de Oliva/uso terapéutico , Fenoles/uso terapéutico , Biomarcadores/sangre , Estudios Cruzados , Grasas Insaturadas en la Dieta/economía , Método Doble Ciego , Femenino , Ingredientes Alimentarios/economía , Calidad de los Alimentos , Industria de Procesamiento de Alimentos/economía , Frutas/química , Humanos , Hipercolesterolemia/sangre , Residuos Industriales/economía , Lipoproteínas HDL/química , Masculino , Persona de Mediana Edad , Olea/química , Aceite de Oliva/economía , Fenoles/economía , Extractos Vegetales/economía , Extractos Vegetales/uso terapéutico , Hojas de la Planta/química , España , Thymus (Planta)/química , alfa-Tocoferol/análisis , alfa-Tocoferol/sangre
14.
Biochem Soc Trans ; 45(5): 1105-1115, 2017 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-28900017

RESUMEN

Inappropriate, excessive or uncontrolled inflammation contributes to a range of human diseases. Inflammation involves a multitude of cell types, chemical mediators and interactions. The present article will describe nutritional and metabolic aspects of omega-6 (n-6) and omega-3 (n-3) fatty acids and explain the roles of bioactive members of those fatty acid families in inflammatory processes. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are n-3 fatty acids found in oily fish and fish oil supplements. These fatty acids are capable of partly inhibiting many aspects of inflammation including leucocyte chemotaxis, adhesion molecule expression and leucocyte-endothelial adhesive interactions, production of eicosanoids like prostaglandins and leukotrienes from the n-6 fatty acid arachidonic acid and production of pro-inflammatory cytokines. In addition, EPA gives rise to eicosanoids that often have lower biological potency than those produced from arachidonic acid, and EPA and DHA give rise to anti-inflammatory and inflammation resolving mediators called resolvins, protectins and maresins. Mechanisms underlying the anti-inflammatory actions of EPA and DHA include altered cell membrane phospholipid fatty acid composition, disruption of lipid rafts, inhibition of activation of the pro-inflammatory transcription factor nuclear factor κB so reducing expression of inflammatory genes and activation of the anti-inflammatory transcription factor peroxisome proliferator-activated receptor γ. Animal experiments demonstrate benefit from EPA and DHA in a range of models of inflammatory conditions. Human trials demonstrate benefit of oral n-3 fatty acids in rheumatoid arthritis and in stabilizing advanced atherosclerotic plaques. Intravenous n-3 fatty acids may have benefits in critically ill patients through reduced inflammation. The anti-inflammatory and inflammation resolving actions of EPA, DHA and their derivatives are of clinical relevance.


Asunto(s)
Antiinflamatorios/uso terapéutico , Ácidos Grasos Omega-3/metabolismo , Inflamación/metabolismo , Ensayos Clínicos como Asunto , Citocinas/metabolismo , Grasas Insaturadas en la Dieta/uso terapéutico , Ácidos Docosahexaenoicos/uso terapéutico , Ácido Eicosapentaenoico/uso terapéutico , Ácidos Grasos Omega-6/metabolismo , Humanos , Inflamación/tratamiento farmacológico
15.
Cuad. psicol. deporte ; 17(3): 95-104, sept. 2017. tab
Artículo en Inglés | IBECS | ID: ibc-169671

RESUMEN

In dinghy sailing, there are many factors all of which affect to sailor performance: experience, training, nutrition and psychological condition. The main aim of this report was to know sailor's anxiety levels according to eating habits, nutritional condition, training, experience and type of vessel. 77 Laser (4.7 and Radial) and 470 sailors filled up CSAI-2 and PREDIMED questionnaires to determine competitive state anxiety and low fat diet adherence. They showed higher BMI the sailors with higher low fat diet adherence, higher experience, higher ranking position and Radial's sailors. Under-16 sailors showed less competitive anxiety. Overweight sailor got less cognitive anxiety. Sailors who trained more times per week got best results. Sailors with higher BMI will get best results with strong wind because they will keep the boat horizontal more easily. Radial's sailors have higher BMI due to their age. Under-16 sailors show less competitive anxiety due to lower demand for results. Overweight sailor show less cognitive anxiety due to lower expectations. Sailors who train more times per week get best results. Low fat Mediterranean diet not seem conditioned competitive anxiety in sailors. Sailing performance seems to be conditioned by sailor weight, wind conditions, training frequency and experience (AU)


En vela hay muchos factores que afectan al rendimiento del regatista, cómo la experiencia, el entrenamiento, la nutrición y el estado psicológico. El objetivo de este estudio fue conocer los niveles de ansiedad en regatistas según hábitos alimentarios, estado nutricional, entrenamiento, experiencia y tipo de embarcación. Participaron 77 regatistas de clase Laser (4.7 y Radial) y 470, rellenaron los cuestionarios CSAI-2 y PREDIMED, para determinar estado de ansiedad competitivo y adherencia a la dieta baja en grasa. Mostraron mayor IMC los regatistas con mayor adherencia a la dieta baja en grasas, mayor experiencia, mejor clasificación, y los de clase Radial. Los sub-16 presentaron menor ansiedad competitiva. Los regatistas con sobrepeso obtuvieron menor ansiedad cognitiva. Los regatistas que realizaban más entrenamientos por semana obtuvieron mejores resultados. Los regatistas con mayor IMC obtendrán mejores resultados con viento fuerte, debido a que mantendrán el barco horizontal con mayor facilidad. Los regatistas de clase Radial tienen mayor IMC debido a su edad. Los regatistas sub-16 muestran menos ansiedad competitiva debido a menor exigencia de resultados. Los regatistas con sobrepeso presentan menor ansiedad cognitiva debido a una menor expectativa. Los regatistas que entrenan entre semana obtienen mejores resultados. La dieta baja en grasa no parece condicionar la ansiedad competitiva de los regatistas. El rendimiento en la navegación parece estar más condicionado por el peso del regatista, las condiciones de viento, la frecuencia de entrenamiento y la experiencia (AU)


Em vela há muitos fatores que afetam ao rendimento do velejadores, como a experiência, o treinamento, a nutrição e o estado psicológico. O objetivo deste estudo era saber os níveis de ansiedade em velejadores de acordo com hábitos alimentares, estado nutricional, enquanto treinando, experimente e faça tipo. Eles participaram 77 velejadores de Laser de classe (4.7 e Radial) e 470, eles encheram os questionários CSAI-2 e PREDIMED, determinar estado competitivo de ansiedade e aderência à baixa dieta em gordura. IMC maior mostrou os velejadores com mais aderência para a baixa dieta em experiência gordurosa, maior, classificação melhor, e esses de classe Radial. Esses substituto-16 eles apresentaram ansiedade menor competitiva. Os velejadores com sobrepeso obtiveram cognitiva de ansiedade menor. Os velejadores que você / eles levaram a cabo mais treinamentos por semana obtiveram resultados melhores. Os velejadores com mais IMC obterão resultados melhores com vento forte, porque eles manterão o navio horizontal com mais facilidade. Os velejadores de classe Radial têm IMC maior devido à idade deles/delas. Os velejadores substituto-16 eles mostram competitivo menos ansiedade devido a demanda menor de resultados. Os velejadores com preponderante apresenta cognitiva de ansiedade menor devido a uma expectativa menor. Os velejadores que treina entre semana obtém resultados melhores. A baixa dieta em gordura não parece condicionar a ansiedade competitiva do velejadores. O rendimento na navegação parece ser condicionado mais pelo peso do velejador, as condições de vento, a frequência de treinar e a experiência (AU)


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto Joven , Dieta Mediterránea/psicología , Ejercicio Físico/psicología , Índice de Masa Corporal , Ansiedad , Grasas Insaturadas en la Dieta/uso terapéutico , Dieta con Restricción de Grasas/métodos , Estudios Transversales/métodos , Estado de Salud , Estado Nutricional/fisiología
16.
Lipids ; 52(6): 549-558, 2017 06.
Artículo en Inglés | MEDLINE | ID: mdl-28493185

RESUMEN

Drug-resistant strains of Helicobacter pylori and poor treatment response are the main reasons for the failure in eradicating it in patients. Polyunsaturated fatty acids (PUFA) have an inhibitory effect on bacterial growth. The aim of this study was to investigate the effect of PUFA in combination with standard triple therapy on apoptosis in H. pylori infected subjects with dyspeptic symptoms. This study was a double-blind clinical trial in which 34 H. pylori infected subjects with dyspeptic symptoms were randomly divided into two groups of 17 patients. The control group received standard triple therapy (amoxicillin, clarithromycin and omeprazole) and the experimental group received the standard therapy and PUFA for two weeks. Gene expression levels of caspase-3, BCL-2 and Bad proteins were studied with real-time PCR, while protein levels were quantified in frozen sections and using immunohistochemistry. Compared with the control group, a significant increase (p < 0.01) was observed in the expression of caspase-3 and Bad genes and a significant reduction (p < 0.05) in the expression of Bcl-2 gene. The protein level of active caspase-3 and Bad protein was significantly increased and the level of Bcl-2 protein was significantly decreased (p < 0.05). The results of this study show that oral administration of PUFA in combination with the standard triple therapy increased apoptosis in H. pylori-infected patients with dyspeptic symptoms. This increase in apoptosis may partly reduce drug resistance in these patients. Our results suggest inclusion of a dietary PUFA containing fatty acid supplement may improve treatment of patients that are refractory to the standard triple therapy.


Asunto(s)
Dispepsia/complicaciones , Dispepsia/terapia , Ácidos Grasos Insaturados/uso terapéutico , Infecciones por Helicobacter/complicaciones , Infecciones por Helicobacter/terapia , Helicobacter pylori/efectos de los fármacos , Estómago/efectos de los fármacos , Adulto , Anciano , Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Apoptosis , Caspasa 3/genética , Claritromicina/uso terapéutico , Grasas Insaturadas en la Dieta/uso terapéutico , Método Doble Ciego , Dispepsia/genética , Dispepsia/patología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Infecciones por Helicobacter/genética , Infecciones por Helicobacter/patología , Humanos , Masculino , Persona de Mediana Edad , Omeprazol/uso terapéutico , Proteínas Proto-Oncogénicas c-bcl-2/genética , Estómago/patología
17.
Obes Surg ; 27(10): 2663-2671, 2017 10.
Artículo en Inglés | MEDLINE | ID: mdl-28470492

RESUMEN

BACKGROUND: Several studies have demonstrated the benefits of replacing trans and saturated fats with unsaturated fatty acids on cardiovascular diseases. We aimed to demonstrate the effect of polyunsaturated and monounsaturated fat supplementation on the biochemical and endothelial markers of atherosclerotic disease in obese or overweight non-diabetic elderly patients. METHOD: Seventy-nine patients were randomly divided into three groups: flaxseed oil, olive oil, and sunflower oil; patients in each group received 30 mL of oil for 90 days. Patients were subjected to anthropometric and bioimpedance assessments; biochemical and endothelial evaluations were performed through ultrasonography of the brachial artery and carotid artery for endothelium-dependent dilation and intima-media thickness assessment, respectively, before and after the intervention. The participants' usual diet remained unchanged. RESULTS: The flaxseed oil group had improved ultra-sensitive C-reactive protein levels (p = 0.074) and reduced carotid intima-media thickness (CIMT) (p = 0.028); the olive oil group exhibited an improved apolipoprotein (Apo)B/ApoA ratio (p = 0.021), reduced CIMT (p = 0.028), and improved flow-mediated vasodilation (FMV) (p = 0.054); and similarly, the sunflower oil group showed an improved ApoB/ApoA ratio (p = 0.024), reduced CIMT (p = 0.048), and improved FMV (p = 0.001). CONCLUSION: Unsaturated fatty acid supplementation using the three vegetable oils attenuated pro-inflammatory properties and improved prothrombotic conditions. Therefore, introducing or replacing saturated and trans fat with unsaturated fatty acids is beneficial for cardiovascular risk reduction in obese or overweight non-diabetic elderly people. Further studies are needed to determine which unsaturated fat best prevents cardiovascular disease in elderly patients.


Asunto(s)
Aterosclerosis/dietoterapia , Biomarcadores/sangre , Enfermedades Cardiovasculares/prevención & control , Grasas Insaturadas en la Dieta/uso terapéutico , Ácidos Grasos Insaturados/uso terapéutico , Obesidad/dietoterapia , Sobrepeso/dietoterapia , Anciano , Anciano de 80 o más Años , Aterosclerosis/complicaciones , Grosor Intima-Media Carotídeo , Suplementos Dietéticos , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Obesidad/sangre , Obesidad/complicaciones , Obesidad/fisiopatología , Sobrepeso/sangre , Sobrepeso/complicaciones , Sobrepeso/fisiopatología , Aceites de Plantas/administración & dosificación , Factores de Riesgo
18.
Nutr Diabetes ; 7(4): e259, 2017 04 10.
Artículo en Inglés | MEDLINE | ID: mdl-28394361

RESUMEN

BACKGROUND: The role of herbal medicine is now well documented in preventing and controlling diabetes mellitus. The main aim of this study was to evaluate the effects of walnut oil consumption on lipid profiles of hyperlipidemic patients with type 2 diabetes. METHODS: In a randomized, double-blind, placebo-controlled clinical trial, 100 hyperlipidemic type 2 diabetic patients aged 35-75 years were assigned to receive 15 cc Persian walnut oil or placebo every day for 90 days. The primary outcomes were the lipid profiles. RESULTS: Consumption of walnut oil by type 2 hyperlipidemic diabetic patients resulted in a significant decrease in total cholesterol levels (treatment difference (TD)=-30.04, P<0.001), triglyceride (TG) level (TD=-15.04, P=0.021), low-density lipoprotein (LDL) level (TD=-30.44, P<0.001) and total cholesterol to high-density lipoprotein (HDL) ratio (TD=-0.72, P<0.001) compared to the control group. There was a trend toward increasing HDL level with consumption of walnut oil (TD=2.28, P=0.06). Frequency of patients reaching a LDL level below 100 was higher in the case group (20 vs 0%). CONCLUSIONS: Addition of walnut oil in the daily diet of type 2 diabetic patients improves lipid profiles. Thus, it may be associated with a coronary artery disease risk factor modulation. Also, walnut oil may serve as a helpful natural remedy for hyperlipidemic patients with type 2 diabetes.


Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hiperlipidemias/tratamiento farmacológico , Juglans/química , Lípidos/sangre , Nueces/química , Fitoterapia , Aceites de Plantas/uso terapéutico , Adulto , Anciano , Colesterol/sangre , LDL-Colesterol/sangre , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/dietoterapia , Grasas Insaturadas en la Dieta/sangre , Grasas Insaturadas en la Dieta/farmacología , Grasas Insaturadas en la Dieta/uso terapéutico , Método Doble Ciego , Humanos , Hiperlipidemias/sangre , Hiperlipidemias/complicaciones , Hiperlipidemias/dietoterapia , Lipoproteínas HDL/sangre , Persona de Mediana Edad , Aceites de Plantas/metabolismo , Aceites de Plantas/farmacología , Triglicéridos/sangre
19.
Vitam Horm ; 104: 343-366, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28215301

RESUMEN

Maternal nutrition is one of the major determinants of pregnancy outcome. It has been suggested that reduced intakes or lack of specific nutrients during pregnancy influences the length of gestation, proper placental and fetal growth during pregnancy. Maternal nutrition, particularly micronutrients such as folate and vitamin B12, and long-chain polyunsaturated fatty acids (LCPUFA) are the major determinants of the one carbon cycle and are suggested to be at the heart of intrauterine programming of diseases in adult life. LCPUFA play a key role in the normal feto-placental development, as well as in the development and functional maturation of the brain and central nervous system and also regulate the levels of neurotrophic factors. These neurotrophic factors are known to regulate the development of the placenta at the materno-fetal interface and act in a paracrine and endocrine manner. Neurotrophic factors like brain-derived neurotrophic factor and nerve growth factor are proteins involved in angiogenesis and potentiate the placental development. This chapter mainly focuses on micronutrients since they play a main physiological role during pregnancy.


Asunto(s)
Antioxidantes/uso terapéutico , Grasas Insaturadas en la Dieta/uso terapéutico , Ácido Fólico/uso terapéutico , Fenómenos Fisiologicos Nutricionales Maternos , Factores de Crecimiento Nervioso/metabolismo , Malformaciones del Sistema Nervioso/prevención & control , Vitamina B 12/uso terapéutico , Antioxidantes/metabolismo , Grasas Insaturadas en la Dieta/metabolismo , Suplementos Dietéticos , Epigénesis Genética , Femenino , Ácido Fólico/metabolismo , Alimentos Fortificados , Humanos , Malformaciones del Sistema Nervioso/metabolismo , Neurogénesis , Estrés Oxidativo , Placentación , Embarazo , Vitamina B 12/metabolismo
20.
Nutrients ; 9(1)2017 Jan 20.
Artículo en Inglés | MEDLINE | ID: mdl-28117688

RESUMEN

Specialty oils differ in fatty acid, phytosterol and antioxidant content, impacting their benefits for cardiovascular health. The lipid (fatty acid, phytosterol) and antioxidant (total phenolics, radical scavenging capacity) profiles of grapeseed (GSO), corn (CO) and coconut (CNO) oils and their physiological (triacylglycerides, total and HDL-cholesterol and antioxidant capacity (FRAP) in serum and fatty acid and phytosterol hepatic deposition) and genomic (HL, LCAT, ApoA-1 and SR-BP1 mRNA hepatic levels) responses after their sub-chronic intake (10% diet for 28 days) was examined in healthy albino rats. Fatty acid, phytosterol and antioxidant profiles differed between oils (p ≤ 0.01). Serum and hepatic triacylglycerides and total cholesterol increased (p ≤ 0.01); serum HDL-Cholesterol decreased (p < 0.05); but serum FRAP did not differ (p > 0.05) in CNO-fed rats as compared to CO or GSO groups. Hepatic phytosterol deposition was higher (+2.2 mg/g; p ≤ 0.001) in CO- than GSO-fed rats, but their fatty acid deposition was similar. All but ApoA-1 mRNA level increased in GSO-fed rats as compared to other groups (p ≤ 0.01). Hepatic fatty acid handling, but not antioxidant response, nor hepatic phytosterol deposition, could be related to a more efficient reverse-cholesterol transport in GSO-fed rats as compared to CO or CNO.


Asunto(s)
Antioxidantes/uso terapéutico , Grasas Insaturadas en la Dieta/uso terapéutico , Regulación de la Expresión Génica , Hiperlipidemias/prevención & control , Metabolismo de los Lípidos , Hígado/metabolismo , Aceites de Plantas/uso terapéutico , Animales , Antioxidantes/efectos adversos , Antioxidantes/análisis , Antioxidantes/química , Biomarcadores/sangre , Biomarcadores/metabolismo , HDL-Colesterol/agonistas , HDL-Colesterol/antagonistas & inhibidores , HDL-Colesterol/sangre , Aceite de Coco , Aceite de Maíz/efectos adversos , Aceite de Maíz/química , Aceite de Maíz/uso terapéutico , Grasas Insaturadas en la Dieta/efectos adversos , Ácidos Grasos/efectos adversos , Ácidos Grasos/análisis , Ácidos Grasos/metabolismo , Ácidos Grasos/uso terapéutico , Hiperlipidemias/sangre , Hiperlipidemias/etiología , Masculino , Capacidad de Absorbancia de Radicales de Oxígeno , Fenoles/efectos adversos , Fenoles/análisis , Fenoles/uso terapéutico , Fitosteroles/efectos adversos , Fitosteroles/análisis , Fitosteroles/metabolismo , Fitosteroles/uso terapéutico , Aceites de Plantas/efectos adversos , Aceites de Plantas/química , Aceites de Plantas/metabolismo , Distribución Aleatoria , Ratas Wistar , Semillas/química , Organismos Libres de Patógenos Específicos , Vitis/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...